Evidence map›Paper›PMID 38585585›Full record

ArticleClinical case reports2024

Durable complete response to PET-CT driven stereotactic radiation therapy plus pembrolizumab for pleomorphic Pancoast cancer: Case report and literature review.

Alessandra Castelluccia, Angela Sardaro, Artor Niccoli Asabella, Antonio Rosario Pisani, Dino Rubini, Maurizio Portaluri, Francesco Tramacere

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical case reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Alessandra CastellucciaDepartment of Radiotherapy "A. Perrino" Hospital Brindisi Italy.ORCID https://orcid.org/0009-0000-3895-2638
Angela SardaroSection of Radiology and Radiation Oncology, Interdisciplinary Department of Medicine University of Bari "Aldo Moro" Bari Italy.
Artor Niccoli AsabellaSection of Nuclear Medicine, Interdisciplinary Department of Medicine University of Bari Aldo Moro Bari Italy.
Antonio Rosario PisaniSection of Nuclear Medicine, Interdisciplinary Department of Medicine University of Bari Aldo Moro Bari Italy.
Dino RubiniDepartment of Precision Medicine Università degli Studi della Campania Luigi Vanvitelli Napoli Campania Italy.
Maurizio PortaluriDepartment of Radiotherapy "A. Perrino" Hospital Brindisi Italy.
Francesco TramacereDepartment of Radiotherapy "A. Perrino" Hospital Brindisi Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PET-driven SBRT plus pembrolizumab as first-line therapy against pleomorphic Pancoast cancer appears beneficial, probably due to high equivalent doses of SBRT on photopenic necrotic core and synergic immune system stimulation of immunoradiotherapy.

Indexed as

image‐guided radiation therapyimmune checkpoint inhibitorsPancoast tumorpleomorphic lung cancerradioimmunotherapystereotactic body radiotherapy

Identifiers

PMID38585585
PMCPMC10996042

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.